Commit Biologics

A Novel Immunotherapy Platform

Founded 2021 · $25.1M raised

Founded
2021
Business Model
B2B
Total Funding
$25.1M
Last Round
$6.4M Extension RoundJan 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Commit Biologics is a biotech spin-out from Aarhus University, founded in 2021, that develops a complement-engaging immunotherapy platform for cancer and autoimmune disease. Its Bispecific Complement Engaging (BiCE) technology uses single-domain antibodies that bind complement protein C1q to direct the innate immune system against tumor cells or cells implicated in autoimmune disease. The approach aims to overcome limits of conventional monoclonal antibodies, which poorly engage C1q, and to offer a broader therapeutic index than T-cell engagers or antibody-drug conjugates.

Summary

Commit Biologics is a Biotech company, founded in 2021. It has raised $25.1M in total across 2 rounds, most recently a $6.4M Extension Round in Jan 2025.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeed ExtensionJan 2025
$6.4M

Sign up to see all 2 events

Funding: Seed through Extension Round. Amounts, valuations, and investors where available.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Commit Biologics on Indexed.vc
<a href="https://indexed.vc/companies/commit-biologics"><img src="https://indexed.vc/api/badge/company/commit-biologics" alt="Commit Biologics on Indexed.vc" width="260" height="76" /></a>